Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Metastatic Anaplastic Thyroid CancerLocally Advanced Anaplastic, Undifferentiated Thyroid Cancer
Interventions
DRUG

Ceritinib

750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER